Healthcare / Diagnostics & ResearchShanghai
$12.64
-0.33 (-2.54%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $3.5M · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
28/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5.0B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-3.2%
↓Gross Margin
14.8%
↓Debt/Equity
0.06
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-19.1%
FCF CAGR
—
FCF margin
0.5%
FCF / Net income
-0.10x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $677.8M · net income $-33.6M · FCF $3.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $677.8M | $677.8M | $939.1M | $1.09B | $1.28B |
| Net Income | $-33.6M | $-33.6M | $27.6M | $47.2M | $82.7M |
| EBITDA | $-27.5M | $-27.5M | $53.2M | $83.1M | $129.8M |
| EPS | -0.08 | -0.08 | 0.07 | 0.12 | 0.22 |
| Gross Margin | 14.8% | 14.8% | 19.6% | 20.7% | 20.1% |
| Operating Margin | -3.5% | -3.5% | 3.8% | 6.2% | 8.8% |
| Net Margin | -5.0% | -5.0% | 2.9% | 4.3% | 6.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.06 | 0.06 | 0.04 | 0.06 | 0.07 |
| Current Ratio | 3.05 | 3.05 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $3.5M | $3.5M | $100.9M | $-56.7M | $-56.3M |
| Returns | |||||
| ROE | -3.2% | -3.2% | 2.4% | 4.0% | 7.0% |
| Valuation | |||||
| P/E | — | — | 93.86 | 67.33 | 52.59 |
| EV/EBITDA | — | — | 44.74 | 36.70 | 31.62 |
| P/B | 5.02 | 5.02 | 2.21 | 2.72 | 3.69 |
| Growth & Yield | |||||
| Revenue Growth | -27.8% | -27.8% | -14.0% | -14.6% | — |
| EPS Growth | -214.3% | -214.3% | -41.7% | -45.5% | — |
| Dividend Yield | 1.0% | 1.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+86.1%
Start / end P/E
n/dx → n/dx
EPS bridge
0.07 → -0.08
Residual
+85.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.